Compounds > sr 48692

Page last updated: 2024-09-03

sr 48692 and Schizophrenia

sr 48692 has been researched along with Schizophrenia in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bubser, M; Carraway, RE; Deutch, AY; Fadel, J; Petrie, KA; Schmidt, D	1
Boules, MM; Fredrickson, PA; Richelson, E	1
Robertson, VB; Wilson, MS	1
Gross, R; Kilts, CD; Lambert, PD; Nemeroff, CB	1

Reviews

1 review(s) available for sr 48692 and Schizophrenia

Article	Year
Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system. Annals of the New York Academy of Sciences, 1995, May-10, Volume: 757 Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Cyclic AMP; Dopamine; Haloperidol; Neurotensin; Pyrazoles; Quinolines; Receptors, Dopamine; Receptors, Neurotensin; Schizophrenia; Signal Transduction	1995

Other Studies

3 other study(ies) available for sr 48692 and Schizophrenia

Article	Year
Neurotensin activates GABAergic interneurons in the prefrontal cortex. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2005, Feb-16, Volume: 25, Issue:7 Topics: Animals; Axons; Dopamine; Dopamine Agonists; gamma-Aminobutyric Acid; Interneurons; Male; Microdialysis; Neurotensin; Parvalbumins; Prefrontal Cortex; Pyrazoles; Quinolines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Neurotensin; Schizophrenia; Tetrodotoxin	2005
Neurotensin receptor agonists and antagonists for schizophrenia. The American journal of psychiatry, 2005, Volume: 162, Issue:3 Topics: Animals; Antipsychotic Agents; Blood-Brain Barrier; Clinical Trials as Topic; Drugs, Investigational; Humans; Neurotensin; Peptide Fragments; Pyrazoles; Quinolines; Receptors, Neurotensin; Schizophrenia; Treatment Outcome	2005
Neurotensin receptor agonists and antagonists for schizophrenia. The American journal of psychiatry, 2005, Volume: 162, Issue:3 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Data Interpretation, Statistical; Humans; Mianserin; Mirtazapine; Neurotensin; Peptide Fragments; Piperidines; Pyrazoles; Quinolines; Receptors, Neurotensin; Research Design; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2005